In Machina Platform
Ex vivo liver perfusion as a new approach for preclinical testing
Heads:
Pr. Eric Vibert; Pr.Marc-Antoine Allard; Dr. Elie Farha
Objectives
Evaluate drug candidates and medical devices on patient-derived cancerous livers, enabling multiple analysis to support decision making and for better derisking.
Operator (s)
Technology and expertises
Innovative, long term, ex vivo organ perfusion technology that preserves resected human livers in a physiological state. Totally or partially diseased livers contain HCC, cholangiocarcinoma or colorectal metastasis.
Services and activities
Long term ex vivo liver perfusion
Totally or partially resected livers will represent a human model that recapitulates whole organ architecture with an established TME and an integrated immune system. Livers will be perfused for 10–14 days in physiological conditions (normothermia, blood perfusion, gas exchange, regulated metabolism, dialysis…).
Efficacy, Toxicity, Pharmacokinetics, Pharmacodynamics studies
Easy access to livers and fluid lines allows for tissue biopsies, direct injections and fluid withdrawal following described protocols. Pharmacokinetics is feasible due to the availability of an integrated dialysis unit and bile collection.
Associated platforms for Pharmacodynamic studies:
- AMMICA Core Facilities (IGR): Histopathology, immunomonitoring, spatial genomics, microscopy, mass cytometry, metabolic profiling, in vivo imaging.
- FUI: Functionnal ultrasound imaging to capture cancer microvasculature.
- Fluorescent imaging system: Assess tissue perfusion and explore new fluorescent antibodies.